Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis

Stüve, Olaf; Hartung, HP; Freedman, M. S.; Li, D.; Hemmer, Bernhard; Kappos, L; Rieckmann, Peter; Montalbán, X; Ziemssen, Tjalf; Selmaj, K. W.

doi:10.1016/j.msard.2014.09.190

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It exerts immunosuppressive effects via its S1P 1 /S1P 5 receptor agonism . In a phase II trial (BOLD) siponimod significantly reduced lesions in the brain of MS patients . A long‐term safety, tolerability, and efficacy phase II trial in patients with relapsing‐remitting MS is still ongoing (ClinicalTrials NCT01185821).…”

Section: Targets and Therapeutic Options In S1p Metabolismmentioning

confidence: 99%

Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism

Vogt

Stark

2016

Med. Res. Rev.

View full text Add to dashboard Cite

During the last two decades the study of the sphingolipid anabolic, catabolic, and signaling pathways has attracted enormous interest. Especially the introduction of fingolimod into market as first p.o. therapeutic for the treatment of multiple sclerosis has boosted this effect. Although the complex regulation of sphingosine-1-phosphate (S1P) and other catabolic and anabolic sphingosine-related compounds is not fully understood, the influence on different (patho)physiological states from inflammation to cytotoxicity as well as the availability of versatile pharmacological tools that represent new approaches to study these states are described. Here, we have summarized various aspects concerning the many faces of sphingolipid function modulation by different pharmacological tools up to clinical candidates. Due to the immense heterogeneity of physiological or pharmacological actions and complex cross regulations, it is difficult to predict their role in upcoming therapeutic approaches. Currently, inflammatory, immunological, and/or antitumor aspects are discussed.

show abstract

Section: Targets and Therapeutic Options In S1p Metabolismmentioning

confidence: 99%